Pfizer, BMS Finalize Agreement for Worldwide Collaboration on Metabolic Disorders Program

Pfizer and Bristol-Myers Squibb (BMS) announced that they have finalized a definitive agreement for the worldwide collaboration to research, develop and commercialize diacylglycerol acyltransferase-1 (DGAT-1) inhibitors.

Pfizer’s DGAT-1 discovery program includes advanced preclinical compounds with potential applications for the treatment of metabolic disorders, including obesity and diabetes. The program also includes DGAT-1 inhibitors in-licensed by Pfizer from Bayer Pharmaceuticals in June 2006, including a preclinical compound (known as PF-04415060 or BAY 74-4113) originally discovered by Bayer, Pfizer said.

DGAT-1 is an enzyme critical to the creation of triglycerides and fat storage. In studies of obese animals, DGAT-1 inhibitors have been shown to induce weight loss and improve glucose tolerance and lipid levels. These observations suggest DGAT-1 inhibitors may have the potential to treat obesity, diabetes and dyslipidemia, the company said.

Under terms of the agreement, Pfizer will be responsible for all research and early-stage development activities for the metabolic disorders program, and the companies will jointly conduct Phase III development and commercialization activities, according to Pfizer.